INSTIL BIO INC (TIL)

Company Profile

Instil Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Dallas, Texas and currently employs 192 full-time employees. The company went IPO on 2021-03-19. Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL), therapies for the treatment of patients with cancer. The company is developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The firm's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

Company Info

INSTIL BIO INC

3963 Maple Avenue, Suite 350

Dallas TEXAS 75219

P: 19724993350

CEO: Bronson Crouch

Employees: 192

Website: https://instilbio.com/